黑色素瘤 TIL（肿瘤浸润淋巴细胞）治疗的最新进展

Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma.

免疫细胞因子特征可预测接受溶瘤腺病毒 TILT-123 联合化疗及无 IL-2 过继性 TIL 治疗的晚期黑色素瘤患者的生存

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-fr

这些发现为 TILT-123 联合 TIL 疗法提供了机制上的见解，并为未来的生物标志物导向临床研究提出了方向。

从切除到免疫：现代黑色素瘤治疗的全谱系

From Excision to Immunity: The Full Spectrum of Modern Melanoma Treatments.

瘤内注射常规树突状细胞重振肿瘤-免疫循环治疗黑色素瘤及其他实体瘤：叙述性综述

Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrativ

转移性葡萄膜黑色素瘤的双特异性 T 细胞衔接器、细胞疗法及其他非检查点免疫疗法：叙述性综述

Bispecific T-Cell Engagers, Cell Therapies, and Other Non-Checkpoint Immunotherapies for Metastatic Uveal Melanoma: A Narrative Review.

实体瘤新型 TIL（肿瘤浸润淋巴细胞）疗法：2025 ASCO 年会最新进展

Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting.

超越检查点抑制：保持治疗选择开放

Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open.

转移性黑色素瘤中 TIL（肿瘤浸润淋巴细胞）与溶瘤腺病毒 TILT-123 联合治疗的安全性和有效性

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

免疫肿瘤治疗药物的临床开发

Clinical development of immuno-oncology therapeutics.

黑色素瘤治疗进展：免疫治疗演变格局下 PD-1 抑制剂、T-VEC、mRNA 疫苗与 TIL（肿瘤浸润淋巴细胞）疗法综述

Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landsc